{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T10:17:07Z","timestamp":1790504227450,"version":"4.1.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T00:00:00Z","timestamp":1612483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p><jats:bold>Importance:<\/jats:bold> The effects of dopaminergic treatment on speech in patients with Parkinson's disease (PD) are often mixed and unclear. The aim of this study was to better elucidate those discrepancies.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Full retrospective data from advanced PD patients before and after an acute levodopa challenge were collected. Acoustic analysis of spontaneous monologue and sustained phonation including several quantitative parameters [i.e., maximum phonation time (MPT); shimmer local dB] as well as the Unified Parkinson's Disease Rating Scale (UPDRS) (total scores, subscores, and items) and the Clinical Dyskinesia Rating Scale (CDRS) were performed in both the defined-OFF and -ON conditions. The primary outcome was the changes of speech parameters after levodopa intake. Secondary outcomes included the analysis of possible correlations of motor features and levodopa-induced dyskinesia (LID) with acoustic speech parameters. Statistical analysis included paired <jats:italic>t<\/jats:italic>-test between the ON and OFF data (calculated separately for male and female subgroups) and Pearson correlation between speech and motor data.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> In 50 PD patients (male: 32; female: 18), levodopa significantly increased the MPT of sustained phonation in female patients (<jats:italic>p<\/jats:italic> &amp;lt; 0.01). In the OFF-state, the UPDRS part-III speech item negatively correlated with MPT (<jats:italic>p<\/jats:italic> = 0.02), whereas in the ON-state, it correlated positively with the shimmer local dB (<jats:italic>p<\/jats:italic> = 0.01), an expression of poorer voice quality. The total CDRS score and axial subscores strongly correlated with the ON-state shimmer local dB (<jats:italic>p<\/jats:italic> = 0.01 and <jats:italic>p<\/jats:italic> &amp;lt; 0.01, respectively).<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> Our findings emphasize that levodopa has a poor effect on speech acoustic parameters. The intensity and location of LID negatively influenced speech quality.<\/jats:p>","DOI":"10.3389\/fneur.2020.616062","type":"journal-article","created":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T18:49:26Z","timestamp":1612550966000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":32,"title":["Dopaminergic Treatment Effects on Dysarthric Speech: Acoustic Analysis in a Cohort of Patients With Advanced Parkinson's Disease"],"prefix":"10.3389","volume":"11","author":[{"given":"Francesco","family":"Cavallieri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Budriesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Gessani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Contardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Fioravanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Menozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Moro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Valzania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"435232","DOI":"10.4061\/2011\/435232","article-title":"Acoustic analysis of PD speech","volume":"2011","author":"Chenausky","year":"2011","journal-title":"Parkinsons Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"389195","DOI":"10.1155\/2013\/389195","article-title":"Progression of voice and speech impairment in the course of Parkinson's disease: a longitudinal study","volume":"2013","author":"Skodda","year":"2013","journal-title":"Parkinsons Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1044\/jshr.1202.246","article-title":"Clusters of diagnostic patterns of dysarthria","volume":"12","author":"Darley","year":"1969","journal-title":"J Speech Hear Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"432","DOI":"10.3389\/fneur.2017.00432","article-title":"Speech and voice response to a levodopa challenge in late-stage Parkinson's disease","volume":"8","author":"Fabbri","year":"2017","journal-title":"Front Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00702-017-1676-0","article-title":"Speech disorders in Parkinson's disease: early diagnostics and effects of medication and brain stimulation","volume":"124","author":"Brabenec","year":"2017","journal-title":"J Neural Transm."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e20170200","DOI":"10.1590\/2317-1782\/20182017200","article-title":"Impact of levodopa treatment in the voice pattern of Parkinson's disease patients: a systematic review and meta-analysis","volume":"30","author":"Pinho","year":"2018","journal-title":"Codas."},{"key":"B7","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1111\/coa.13082","article-title":"Voice quality outcomes of idiopathic Parkinson's disease medical treatment: a systematic review","volume":"43","author":"Lechien","year":"2018","journal-title":"Clin Otolaryngol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00702-009-0351-5","article-title":"Short- and long-term dopaminergic effects on dysarthria in early Parkinson's disease","volume":"117","author":"Skodda","year":"2010","journal-title":"J Neural Transm."},{"key":"B9","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1155\/1999\/327643","article-title":"Speech impairment in a large sample of patients with Parkinson's disease","volume":"11","author":"Ho","year":"1999","journal-title":"J Behav Neurol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00702-016-1515-8","article-title":"Effects of dopaminergic replacement therapy on motor speech disorders in Parkinson's disease: longitudinal follow-up study on previously untreated patients","volume":"123","author":"Rusz","year":"2016","journal-title":"J Neural Transm"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1097\/00005537-199908000-00019","article-title":"Glottographic measures before and after levodopa treatment in Parkinson's disease","volume":"109","author":"Jiang","year":"1999","journal-title":"Laryngoscope."},{"key":"B12","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/mds.21899","article-title":"For better or worse: the effect of levodopa on speech in Parkinson's disease","volume":"23","author":"Ho","year":"2008","journal-title":"Mov Disord."},{"key":"B13","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1590\/S0004-282X2010000500006","article-title":"Acoustic and hearing- perceptual voice analysis in individuals with idiopathic Parkinson's disease in \u201con\u201d and \u201coff\u201d stages","volume":"68","author":"Santos","year":"2010","journal-title":"Arq Neuropsiquiatr."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s00702-015-1363-y","article-title":"Effect of dopaminergic medication on speech dysfluency in Parkinson's disease: a longitudinal study","volume":"122","author":"Tykalov\u00e1","year":"2015","journal-title":"J Neural Transm"},{"key":"B15","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1136\/jnnp.68.5.595","article-title":"Axial parkinsonian symptoms can be improved: the role of levodopa and bilateral subthalamic stimulation","volume":"68","author":"Bejjani","year":"2000","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B16","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","article-title":"Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases","volume":"55","author":"Hughes","year":"1992","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"B18","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1002\/1531-8257(199907)14:4<572::AID-MDS1005>3.0.CO;2-C","article-title":"Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD)","volume":"14","author":"Defer","year":"1999","journal-title":"Mov Disord."},{"key":"B19","first-page":"293","volume-title":"Recent Developments in Parkinson's Disease","author":"In: Fahn","year":"1987"},{"key":"B20","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/1531-8257(199905)14:3<448::AID-MDS1010>3.0.CO;2-0","article-title":"Clinical rating of dyskinesias in Parkinson's disease: use and reliability of a new rating scale","volume":"14","author":"Hagell","year":"1999","journal-title":"Mov Disord."},{"key":"B21","unstructured":"BoersmaP\n            WeeninkD\n          Praat: Doing Phonetics by Computer [Computer Program]. Version 5.3.512013"},{"key":"B22","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1007\/s00415-015-7671-1","article-title":"Speech disorders reflect differing pathophysiology in Parkinson's disease, progressive supranuclear palsy and multiple system atrophy","volume":"262","author":"Rusz","year":"2015","journal-title":"J Neurol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/mds.23429","article-title":"Systematic review of levodopa dose equivalency reporting in Parkinson's disease","volume":"25","author":"Tomlinson","year":"2010","journal-title":"Mov Disord."},{"key":"B24","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.clineuro.2007.04.003","article-title":"The effect of levodopa on respiration and word intelligibility in people with advanced Parkinson's disease","volume":"109","author":"De Letter","year":"2007","journal-title":"Clin Neurol Neurosurg."},{"key":"B25","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jvoice.2010.04.007","article-title":"Intonation and speech rate in Parkinson's disease: general and dynamic aspects and responsiveness to levodopa admission","volume":"25","author":"Skodda","year":"2011","journal-title":"J Voice."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1016\/j.jvoice.2015.10.022","article-title":"relationship between voice and motor disabilities of Parkinson's disease","volume":"768","author":"Majdinasab","year":"2016","journal-title":"J Voice."},{"key":"B27","unstructured":"Correlation between acoustic speech characteristics and non-speech motor performance in Parkinson diseaseCR109116\n            GobermanAM\n          15735562Med Sci Monit.112005"},{"key":"B28","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/j.1600-0404.2007.00965.x","article-title":"Voice abnormalities and their relation with motor dysfunction in Parkinson's disease","volume":"117","author":"Midi","year":"2008","journal-title":"Acta Neurol Scand."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1002\/mds.20601","article-title":"Changes induced by levodopa and subthalamic nucleus stimulation on parkinsonian speech","volume":"20","author":"Pinto","year":"2005","journal-title":"Mov Disord."},{"key":"B30","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3109\/17549507.2010.491556","article-title":"Sequential changes in motor speech across a levodopa cycle in advanced Parkinson's disease","volume":"12","author":"De Letter","year":"2010","journal-title":"Int J Speech Lang Pathol."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2020.616062\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T18:49:34Z","timestamp":1612550974000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2020.616062\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,5]]},"references-count":30,"alternative-id":["10.3389\/fneur.2020.616062"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2020.616062","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,5]]},"article-number":"616062"}}